AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15754239
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy followed by operative intervention
Trial: 7772514
Drug: High-dose vincristine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vincristine (4 mg/m2 over 4 d) combined with fractionated total body irradiation (F-TBI) (200 cGy x 2 over 3 d) and cyclophosphamide (60 mg/kg for 2 d) in AlloBMT
Trial: 7772514
Drug: High-dose vincristine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vincristine (4 mg/m2 over 4 d) combined with fractionated total body irradiation (F-TBI) (200 cGy x 2 over 3 d) and cyclophosphamide (60 mg/kg for 2 d) in ABMT
Trial: 2189452
Drug: Saline 10
RxNorm normalized name: normal saline 10 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 10 ml
Trial: 457017
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Allopurinol
Trial: 457017
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Benzbromarone
Trial: 457017
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Allopurinol and Benzbromarone
Trial: 26840133
Drug: Metformin (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (3.0 g per day)
Trial: 24354519
Drug: Tissue kallikrein
RxNorm normalized name: Tissue kallikrein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue kallikrein treatment (intravenous infusion of tissue kallikrein 0.15 PNAU/d for 7 days, followed by oral pancreatic kallikrein enteric-coated tablet 240 U, 3 times a day)
Trial: 24354519
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no tissue kallikrein treatment)
Trial: 20980943
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg intravenous N-acetylcysteine (NAC)
Trial: 16265685
Drug: Quinapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (10 mg/day)
Trial: 1619103
Drug: Low-dose cranial
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cranial radiation therapy
Trial: 25029210
Drug: Fr +
RxNorm normalized name: sodium polystyrene sulfonate
DrugBank: Tolevamer (DB01344)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fr + G (13C‐labelled fructose, unlabeled glucose, lipids and protein)
Trial: 25029210
Drug: Fr +
RxNorm normalized name: sodium polystyrene sulfonate
DrugBank: Tolevamer (DB01344)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fr + G
Trial: 23157043
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dinoprostone vaginal insert single dose
Trial: 20517830
Drug: Clomifene +
RxNorm normalized name: clomifene
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomifene + Metformin (Metformin 850 mg twice a day for 8 weeks, Clomifene 100 mg per day for 5 days)
Trial: 20517830
Drug: Clomifene only
RxNorm normalized name: Clomifene only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomifene only (100 mg per day for 5 days)
Trial: 12527974
Drug: 12% CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12% CHO solution
Trial: 12527974
Drug: 0% CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0% CHO solution
Trial: 1508061
Drug: Transdermal oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal oestrogen (50 or 100 micrograms/24 h) combined with oral progestogen (5 mg medroxyprogesterone acetate for 14 days each cycle)
Trial: 30768383
Drug: Extended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended treatment with continued CBT or pharmacotherapy with sertraline
Trial: 31492103
Drug: Glucose-insulin-potassium (GIK)
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium (GIK) infusion (20 IU insulin with 10 mEq KCL in 50 ml glucose 40%)
Trial: 31492103
Drug: Glucose-insulin-potassium (GIK)
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium (GIK) pretreatment after cardiopulmonary bypass
Trial: 28196160
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + SMV (1.2 mg Simvastatin gel)
Trial: 26270952
Drug: Normalisation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normalisation of SF by 3-weekly erythrocytapheresis
Trial: 26270952
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment with 3-weekly plasmapheresis (no normalisation of SF)
Trial: 23568224
Drug: Ketoconazole 400
RxNorm normalized name: ketoconazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 400 mg for 4 days, coadministration with macitentan on day 5, continued for 19 additional days
Trial: 23568224
Drug: Macitentan 10
RxNorm normalized name: macitentan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macitentan 10 mg single oral dose
Trial: 19583868
Drug: Restricted postoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Restricted postoperative IV fluid regime (1.5 L/24 h)
Trial: 19583868
Drug: Standard postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard postoperative IV fluid regime (2.5 L/24 h)
Trial: 15218314
Drug: Adjuvant tegafur
RxNorm normalized name: tegafur
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Adjuvant tegafur (TG) 500 mg/m²/day p.o. for 6 months plus four courses of mitomycin C (MMC) 10-20 mg/m² i.v. every 6 weeks
Trial: 11674935
Drug: Intravenous antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotic therapy (IVAT)
Trial: 7846741
Drug: Famotidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (1 mg/kg/day) administered either intravenously or orally at a dose of 0.5 mg/kg twice a day (maximum: 40 mg/day)
Trial: 7846741
Drug: Famotidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (1 mg/kg/day) administered either intravenously or orally
Trial: 7846741
Drug: Famotidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (0.5 mg/kg twice a day for 8 weeks)
Trial: 3072347
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg twice a day
Trial: 3072347
Drug: Ketanserin 20
RxNorm normalized name: ketanserin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 20 mg twice a day
Trial: 3072347
Drug: Ketanserin (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (any dose) in white patients
Trial: 3072347
Drug: Ketanserin (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (any dose) in black patients
Trial: 21266215
Drug: Ambulatory care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory care (outpatient treatment)
Trial: 16715021
Drug: Manual lymph
RxNorm normalized name: Bos taurus lymph preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual lymph drainage (ML)
Trial: 3301001
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (DHE) nasal spray, 1.36 mg/attack
Trial: 25600272
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (6% HP with and without n-HA)
Trial: 23922054
Drug: Onartuzumab (IV)
RxNorm normalized name: Onartuzumab
DrugBank: Onartuzumab (DB11746)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onartuzumab (IV) at doses between 4 and 30 mg/kg
Trial: 23922054
Drug: Onartuzumab (IV)
RxNorm normalized name: Onartuzumab
DrugBank: Onartuzumab (DB11746)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onartuzumab (IV) co-administered with oral erlotinib
Trial: 19608210
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg GSE per day
Trial: 19608210
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg GSE per day
Trial: 18076799
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy using 5‐fluorouracil (5‐FU)
Trial: 18076799
Drug: No perioperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No perioperative chemotherapy (Control)
Trial: 12185407
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intravenous citalopram
Trial: 7697947
Drug: Single-dose zileuton
RxNorm normalized name: Zileuton
DrugBank: Zileuton (DB00744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose zileuton
Trial: 7697947
Drug: Multiple-dose zileuton
RxNorm normalized name: Zileuton
DrugBank: Zileuton (DB00744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple-dose zileuton
Trial: 2094221
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg almitrine bismesylate (Vectarion)
Trial: 2094221
Drug: Placebo-pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-pill
Trial: 18042413
Drug: Millimetre wave
RxNorm normalized name: ELECTRODE GEL,H-WAVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Millimetre wave therapy (MWT)
Trial: 12949688
Drug: Potentiated morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentiated morphine
Trial: 9310224
Drug: 5‐FU/epi injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU/epi injectable gel (up to 2 cycles of ≤6 treatments)
Trial: 9310224
Drug: 5‐FU/epi injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU/epi injectable gel (first cycle of treatment)
Trial: 24555229
Drug: Emoxipin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emoxipin (150 mg daily)
Trial: 24555229
Drug: Reamberin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reamberin (400 ml daily)
Trial: 24555229
Drug: Mexidol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexidol (300 mg daily)
Trial: 21953329
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg/kg/h)
Trial: 16567174
Drug: Betamethasone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (3 weekly doses starting at 34 weeks)
Trial: 16567174
Drug: Prenatal steroids
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal steroids (in cohort study)
Trial: 16567174
Drug: No prenatal
RxNorm normalized name: Vitafol-Nano Prenatal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prenatal steroids (in cohort study)
Trial: 14653082
Drug: Losartan (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (12 weeks treatment)
Trial: 16967785
Drug: 100 mCi
RxNorm normalized name: FLUDEOXYGLUCOSE F 18 (10-100 MCI/ML) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mCi Iodine-131 (high dose)
Trial: 16967785
Drug: 50 mCi
RxNorm normalized name: samarium Sm153 50 MCI/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mCi Iodine-131 (low dose)
Trial: 14597947
Drug: Trimetazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (20 mg 3 times per day)
Trial: 10523009
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ACTH-(1-24) stimulation tests (0.1, 0.5, and 1.0 microg/1.73 m2)
Trial: 10523009
Drug: Insulin hypoglycemia
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin hypoglycemia test (0.15 U/kg insulin)
Trial: 10523009
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ACTH stimulation test (250-microg ACTH-(1-24))
Trial: 10523009
Drug: 8-hour ACTH-(1-24)
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-hour ACTH-(1-24) infusion (250 microg at a constant rate over 8 h)
Trial: 7552477
Drug: L-697,661 (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-697,661 (50, 300, or 1,000 mg daily)
Trial: 6108901
Drug: +cyanidanol-3 (Catechin),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +cyanidanol-3 (Catechin), 2 g/day
Trial: 23416015
Drug: CysC ≤
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CysC ≤ 95 mg/l and NT-proBNP ≤ 32 pg/ml
Trial: 23525025
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg Alendronate weekly for eight weeks
Trial: 23525025
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Alendronate daily for eight weeks
Trial: 16893712
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg warfarin initiation nomogram
Trial: 3318546
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg/kg body wt.)
Trial: 3318546
Drug: Methohexital (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexital (1 mg/kg)
Trial: 24716641
Drug: Corticosteroids (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (mean daily dose)
Trial: 20850833
Drug: Percutaneous tibial
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous tibial nerve stimulation (12 sessions, 30 minutes each, 3 times weekly)
Trial: 18847313
Drug: Plerixafor (AMD3100)
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plerixafor (AMD3100) combined with G-CSF
Trial: 12610195
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (300 mg/d) during cisplatin chemotherapy
Trial: 12610195
Drug: Cisplatin chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin chemotherapy alone
Trial: 28160272
Drug: Immediate initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immediate initiation of antiretroviral therapy
Trial: 28160272
Drug: Deferred initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Deferred initiation of antiretroviral therapy
Trial: 26331791
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg racemic venlafaxine (VLX)
Trial: 9887236
Drug: IFN-alpha plus
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha plus ATRA (150 mg/m2/day orally in two divided doses)
Trial: 9887236
Drug: IFN-alpha plus
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha plus 13cRA (1 mg/kg/day orally)
Trial: 8005187
Drug: Pemirolast potassium
RxNorm normalized name: Pemirolast Potassium
DrugBank: Pemirolast (DB00885)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pemirolast potassium (TBX) 10 mg twice daily at 12 h intervals
Trial: 8005187
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline formulation 100 mg twice daily at 12 h intervals
Trial: 2689493
Drug: Selective decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective decontamination with polymyxin E, norfloxacin, amphotericin B and systemic antibiotic prophylaxis with trimethoprim
Trial: 22403308
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg oral artesunate for three days followed by artemether-lumefantrine
Trial: 22403308
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg oral artesunate for three days followed by artemether-lumefantrine
Trial: 17554539
Drug: Maximum-tolerated doses
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum-tolerated doses (MTD) chemotherapy including 75 mg/m2 of cisplatin and 75 mg/m2 of docetaxel on day 1
Trial: 17554539
Drug: Low-dose metronomic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose metronomic (LDM) chemotherapy consisting of cisplatin 25 mg/m2 and docetaxel 25 mg/m2 given on weeks 1, 2, and 3
Trial: 17056968
Drug: Pregabalin/Celecoxib combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin/Celecoxib combination (400 mg/150 mg 1 h before and 200 mg/150 mg 12 h after surgery)
Trial: 17056968
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg 1 h before and 200 mg 12 h after surgery)
Trial: 17056968
Drug: Pregabalin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (150 mg 1 h before and 150 mg 12 h after surgery)
Trial: 17056968
Drug: Pregabalin/Celecoxib combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin/Celecoxib combination
Trial: 2204472
Drug: ZnSO4 (660
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZnSO4 (660 mg) per day
Trial: 17276217
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment with a fixed sling for 1 week followed by rehabilitation
Trial: 15507072
Drug: Analgesic use
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic use (any)
Trial: 15507072
Drug: Opioid analgesic
RxNorm normalized name: OPIOID ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid analgesic use
Trial: 15507072
Drug: Diagnosis or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnosis or treatment for chronic pain
Trial: 15507072
Drug: Differences in
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Differences in analgesic use across organizations
Trial: 11411655
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy (urethrocystoscopy)
Trial: 18155445
Drug: Adjunctive lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive lamotrigine (LTG)
Trial: 17063975
Drug: Dalteparin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (50 IU anti‐Xa/kg, single intravenous bolus)
Trial: 11035679
Drug: 3.68 microm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.68 microm saline solution droplets inhaled for 30 s at 12 L/min
Trial: 11035679
Drug: 3.68 microm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.68 microm saline solution droplets inhaled for 30 s at 31 L/min
Trial: 11035679
Drug: 1.01 microm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.01 microm saline solution droplets inhaled for 30 s at 18 L/min
Trial: 11035679
Drug: 1.01 microm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.01 microm saline solution droplets inhaled for 30 s at 38 L/min
Trial: 1621545
Drug: Intracavernous E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracavernous E1 prostaglandin E1 (E1‐PG) injection
Trial: 6326932
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiotherapy (40 Gy, one fraction a day over 20 days)
Trial: 30560750
Drug: Multimodal analyses
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analyses with cognition plus any combination of one or more of the remaining three modalities
Trial: 8834816
Drug: HSD-hCG vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSD-hCG vaccine
Trial: 31644339
Drug: PO (unfed)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO (unfed) misoprostol (5 μg/kg)
Trial: 31644339
Drug: PO (fed)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO (fed) misoprostol (5 μg/kg)
Trial: 31644339
Drug: PR misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PR misoprostol (5 μg/kg)
Trial: 23424263
Drug: Acupuncture in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture in combination with conventional therapy
Trial: 17048209
Drug: Ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5 mg/day (3 mg/m2 in children)
Trial: 17048209
Drug: Irbesartan 300
RxNorm normalized name: irbesartan 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 300 mg/day (175 mg/m2 in children)
Trial: 29102957
Drug: Stepwise dose
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stepwise dose increase of febuxostat from 10 to 40 mg/day
Trial: 29102957
Drug: Colchicine 0.5
RxNorm normalized name: colchicine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5 mg/day plus fixed-dose febuxostat 40 mg/day
Trial: 29102957
Drug: Fixed-dose febuxostat
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed-dose febuxostat 40 mg/day